RT Journal Article
SR Electronic
T1 Celebrex adjuvant therapy on COVID-19: An experimental study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20077610
DO 10.1101/2020.05.05.20077610
A1 Hong, Wenxin
A1 Chen, Yan
A1 You, Kai
A1 Tan, Shenglin
A1 Wu, Feima
A1 Tao, Jiawang
A1 Chen, Xudan
A1 Zhang, Jiaye
A1 Xiong, Yue
A1 Yuan, Fang
A1 Yang, Zhen
A1 Chen, Tingting
A1 Chen, Xinwen
A1 Peng, Ping
A1 Tai, Qiang
A1 Wang, Jian
A1 Zhang, Fuchun
A1 Li, Yinxiong
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.05.20077610.abstract
AB Background The world is under serious threat with the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). However, there is no effective drug for the treatment of COVID-19. Based on analyses of available data, we deduced that the excessive prostaglandins E2 (PGE2) accumulation mediated by cyclooxygenase-2 (COX-2) was the key pathological basis of COVID-19.Methods The urine PGE2 levels were measured by mass spectrometry. An experimental study about Celebrex to treat COVID-19 was conducted based on routine treatment. A total of 44 confirmed COVID-19 patients were enrolled (Experimental group n=37, Control group n=7). Patients in experimental group were given Celebrex once or twice a day (0.2 g/time) for 7–14 days. The dosage or duration was modified for individuals. Clinical outcomes of Celebrex adjuvant therapy were evaluated by vital signs, laboratory tests, and computed tomography upon the discontinuance of Celebrex.Results We found that the concentrations of PGE2 in urine samples of COVID-19 patients were significantly higher than that of healthy individuals (mean value is 170 ng/ml vs 18.8 ng/ml, p<0.01) and positively correlated with the progression of COVID-19. Among the experimental group (ordinary n=29, severe n=7, critical n=1), 25 cases were treated with full dose and 11 cases with half dose of Celebrex, and 1 case with Ibuprofen. The remission rate were 100%, 82% and 57% in full dose, half dose and control group respectively. Celebrex significantly reduced the PGE2 levels and promoted recovery of ordinary or severe COVID-19.Conclusion Our study suggests that Celebrex adjuvant treatment may be helpful for the therapy of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000031630Funding StatementThis study was supported by The Emergency and Special Research Project for Prevention and Control of COVID-19 from Guangdong province (2020B111117001); The National Key Research and Development Program of China (2020YFC0842400); Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110106005, 2018GZR110105011); National Major Scientific and Technological Special Project (2018ZX10102-001); National Natural Science Foundation of China (31871379); Science and Technology Project of Guangdong province (2018A050506070); Guangzhou Science and Technology Project (201704020212); Chinese Postdoctoral Science Foundation (2019M663142, 2019M652848).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.